Evidence map›Paper›PMID 31242229›Full record

ArticlePloS one2019

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.

Christopher S Nabel, Stephen Sameroff, Dustin Shilling, Daisy Alapat, Jason R Ruth, Mitsuhiro Kawano, Yasuharu Sato, Katie Stone, Signe Spetalen, Federico Valdivieso and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. TAFRO Syndrome and COVID-19.Biomedicines · 2024
    Review
  14. Review
  15. The Cytokine Storm of Multicentric Castleman Disease.Advances in experimental medicine and biology · 2024
    Review
  16. Article
  17. Article
  18. How we manage idiopathic multicentric Castleman disease.Clinical advances in hematology & oncology : H&O · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 3 countries.

Christopher S NabelDana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America.ORCID 0000-0001-6515-8579
Stephen SameroffColumbia University, New York, New York, United States of America.
Dustin ShillingCastleman Disease Collaborative Network, Philadelphia, Pennsylvania, United States of America.
Daisy AlapatMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Jason R RuthCastleman Disease Collaborative Network, Philadelphia, Pennsylvania, United States of America.
Mitsuhiro KawanoKanazawa University, Kanazawa, Japan.
Yasuharu SatoDivision of Pathophysiology, Okayama University Graduate School of Health Sciences, Okayama, Japan.
Katie StoneMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Signe SpetalenOslo University Hospital, Oslo, Norway.
Federico ValdiviesoHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Michael D FeldmanHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Amy ChadburnDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, United States of America.
Alexander FossåOslo University Hospital, Oslo, Norway.
Frits van RheeMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
W Ian LipkinColumbia University, New York, New York, United States of America.
David C FajgenbaumCastleman Disease Collaborative Network, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-7367-8184
University of Arkansas for Medical Sciences · USColumbia University · USHospital of the University of Pennsylvania · USOslo University Hospital · NOCornell University · USKanazawa University · JPMassachusetts General Hospital · USOkayama University · JPUniversity of Pennsylvania · US

Funding

mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1M
NHLBI NIH HHS R01 HL141408
6 · The paper itself

Abstract

Castleman disease (CD) describes a spectrum of heterogeneous disorders defined by characteristic lymph node histopathology. Enlarged lymph nodes demonstrating CD histopathology can occur in isolation (unicentric CD; UCD) sometimes accompanied by mild symptoms, or at multiple sites (multicentric CD, MCD) with systemic inflammation and cytokine-driven multi-organ dysfunction. The discovery that Kaposi sarcoma herpesvirus/human herpesvirus (HHV)-8 drives MCD in a subset of patients has led to the hypotheses that UCD and MCD patients with negative HHV-8 testing by conventional methods may represent false negatives, or that these cases are driven by another virus, known or unknown. To investigate these hypotheses, the virome capture sequencing for vertebrate viruses (VirCapSeq-VERT) platform was employed to detect RNA transcripts from known and novel viruses in fresh frozen lymph node tissue from CD patients (12 UCD, 11 HHV-8-negative MCD [idiopathic MCD; iMCD], and two HHV-8-positive MCD) and related diseases (three T cell lymphoma and three Hodgkin lymphoma). This assay detected HHV-8 in both HHV-8-positive cases; however, HHV-8 was not found in clinically HHV-8-negative iMCD or UCD cases. Additionally, no novel viruses were discovered, and no single known virus was detected with apparent association to HHV-8-negative CD cases. Herpesviridae family members, notably including Epstein-Barr virus (EBV), were detected in 7 out of 12 UCD and 5 of 11 iMCD cases with apparent correlations with markers of disease severity in iMCD. Analysis of a separate cohort of archival formalin-fixed, paraffin-embedded lymph node tissue by In situ hybridization revealed significantly fewer EBV-positive cells in UCD and iMCD compared to tissue from HHV-8-positive MCD and EBV-associated lymphoproliferative disorder. In an additional cohort, quantitative testing for EBV by PCR in peripheral blood during disease flare did not detect systemic EBV viremia, suggesting detection lymph node tissue is due to occult, local reactivation in UCD and iMCD. This study confirms that HHV-8 is not present in UCD and iMCD patients. Further, it fails to establish a clear association between any single virus, novel or known, and CD in HHV-8-negative cases. Given that distinct forms of CD exist with viral and non-viral etiological drivers, CD should be considered a group of distinct and separate diseases with heterogeneous causes worthy of further study.

Indexed as

AdultAgedCase-Control StudiesCastleman DiseaseDNA, ViralEpstein-Barr Virus InfectionsFalse Negative ReactionsFemaleGenome, ViralHerpesviridae InfectionsHerpesvirus 4, HumanHerpesvirus 8, HumanHumansLymph NodesMaleMiddle AgedDNA, Viral

Identifiers

PMID31242229
PMCPMC6594611
OpenAlexW2954200540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.